I
nherited defects in the thrombomodulin (TM)-protein C system, such as heterozygous deficiency of protein C and S or the factor V Leiden mutation, are among the most commonly recognized causes of venous thrombosis. 1,2 TM gene polymorphisms appear to be rare in the general population, and the thrombosis risk associated with these mutations may largely depend on the presence of compounding variables. [3] [4] [5] [6] [7] [8] Prospective studies suggest that low levels of TM expression may be associated with increased incidence of coronary heart disease. 9 The first gene mutation causing reduced TM function (insT1689) was discovered in a kindred with familial myocardial infarction. 10 These observations suggest that reduced TM function contributes significantly to the pathogenesis of arterial thrombosis, whereas protein C deficiency or resistance to activated protein C (APC) is predominantly associated with venous thrombosis. These differences could reflect protein C-independent functions of TM, such as its interaction with the thrombin-activatable inhibitor of fibrinolysis 11 or protein C-dependent processes unrelated to the inactivation of factor Va. Protein C/APC possesses anti-inflammatory activities that depend on the engagement of specific receptors for APC and/or protein C on monocytes and endothelial cells. [12] [13] [14] [15] [16] [17] We previously introduced a mutation into the mouse TM gene (TM Pro , Glu4043 Pro) that reduces the expression of TM and disrupts its ability to augment the activation of protein C. 18 
TM
Pro/Pro mice show augmented intravascular fibrin deposition but remain free from overt thrombosis. A superimposed defect in tissue plasminogen activator-dependent fibrinolysis exacerbated fibrin deposition in specific organs of TM Pro/Pro mice and caused focal myocardial necrosis. 19 The goal of the present study was to exploit this mouse model of TM deficiency. First, we compared the consequences of reduced TM expression/function on plateletdependent thrombus formation after endothelial injury and coagulation-driven thrombus formation after vascular stasis (the 2 dominant pathogenic mechanisms underlying arterial and venous thrombosis, respectively). Second, we sought to determine whether the genetic suppression of TM function in mice was indeed associated with increased sensitivity to endotoxin-induced septicemia, as predicted from the above observations on the role of the protein C pathway in inflammation. Third, we examined to what extent the phenotypic penetrance of the TM Pro mutation was determined by the interaction with other mouse strain-specific thrombosis modifier genes.
Methods

Transgenic Animals
Mouse strains with altered TM genes, referred to as TM Pro/Pro and TM lacZ , have been described earlier. 18 
Acute Carotid Injury Model
FeCl 3 -induced arterial injury was induced according to published procedures. 21, 22 The right and left common carotid arteries were exposed by blunt dissection, and blood flow was recorded with miniature Doppler flow probes (model 0.5VB, Transonic Systems) positioned around the distal end of the arteries. Ten minutes after probe placement, a 1.0ϫ0.6-mm 2 strip of filter paper soaked in 20% FeCl 3 was applied to the adventitial surface of the artery for 1 minute. The field was flushed with saline, and flow was continuously monitored. In some experiments, the procedure was then repeated on the right common carotid artery. Occlusion times were expressed as t 50 (the time at which pulse amplitude flow dropped to 50% of the initial flow, defined as the average flow occurring between minute 2 and minute 4 after injury). Mixed-models ANOVA was used to assess the relationship of genotype, side, and genotype-side interaction on outcome variables. To adjust for the potential effect of variations in initial flow on t 50 , t 50 was used as the dependent variable, and genotype, initial flow, and side were used as potential predictors.
Carotid Artery Ligation
The left common carotid artery was dissected and ligated near the carotid bifurcation as described. 23 After 4 weeks, all animals were perfused at physiological pressure with 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer, pH 7.3. The left and right common carotid arteries were dissected and embedded in paraffin, and serial sections (5 m thick) were cut at 150-m intervals spanning the entire length of the vessel. Digitized images of these vessels were analyzed by using image analysis software (NIH Image 1.60) as described. 23 
Lipopolysaccharide Challenge
Animals were injected intraperitoneally with the indicated amounts of bacterial endotoxin (Escherichia coli serotype 055:B5, Sigma Chemical Co) in 200 L sterile PBS. At 0.5, 2.0, 6.0, or 24 hours after endotoxin injection, the mice were anesthetized, and blood was collected via cardiac or retro-orbital puncture as described below. For cytokine analysis, blood was collected via cardiac or retro-orbital puncture, and concentrations of tumor necrosis factor (TNF)-␣, interleukin (IL)-1␤, and IL-6 were measured by using Quantikine M mouse immunoassay kits according to the manufacturer's instructions (R&D Systems). Ten minutes before the collection of samples for analysis of fibrin deposition in tissues, total plasma fibrinogen, D-dimer, and the thrombin-antithrombin (TAT) complex, mice were injected intraperitoneally with 8000 U heparin (unfractionated porcine heparin, sodium salt, molecular weight 6000 to 30 000, Life Technologies). Blood samples for measurement of D-dimer and TAT complex were then collected into 1/10 volume of 3.2% sodium citrate and analyzed by ELISA systems (Asserachrom D-Di, American Bioproducts Co; Enzygnost TAT micro, Behring Diagnostics Inc). Values given reflect the apparent levels of mouse TAT and D-dimer obtained by comparison to a standard curve with human TAT and D-dimer. With the use of purified D-dimer prepared from mouse fibrin, the anti-human D-dimer assay system was found to detect the murine antigen with Ϸ20-fold reduced sensitivity. Fibrinogen levels were measured by sandwich ELISA with the use of rabbit anti-human fibrinogen antibody (DAKO Corp) and peroxidase-conjugated goat anti-mouse fibrinogen antibody (Accurate International). The assay was calibrated with purified mouse fibrinogen. The amount of cross-linked fibrin present in mouse tissues was determined by semiquantitative Western blot analysis essentially as described in a previous publication. 18 Detection of fibrinopeptide A (FPA) and plasmin-antiplasmin (PAP) complex was accomplished as described earlier. 24 Platelet counts and other hematologic parameters were determined with an Animal Blood Counter Instrument (HESKA Co).
Determination of Serum
Analysis of Endothelial CellLeukocyte Interactions
Leukocyte-endothelial cell interactions in venules of the ear and cremaster muscle preparations were analyzed by using intravital fluorescence microscopy as described in previous publications. 25, 26 In some experiments, E-selectin-mediated leukocyte-endothelial cell interactions were blocked with the monoclonal antibody 9A9 (50 g per mouse) as described earlier. 26, 27 
Results
Characterization of Hemostatic System Activity in Inbred C57BL/6J TM Pro/Pro Mice
Inbred C57BL/6J TM Pro/Pro mice with a Ն98% contribution of the C57BL/6J genetic background were generated by repeated crosses with wild-type C57BL/6J mice (see Methods). Plasma levels of TAT, D-dimer, FPA, and PAP complex levels were, on average, higher in TM Pro/Pro mice than in wild-type mice (respective values are as follows: TAT, 2.1Ϯ0.6 versus 1.8Ϯ0. 4 , PϽ0.05). Plasma fibrinogen concentration and range of concentration were similar in both groups of animals. Bleeding after standardized tail transection was determined as a crude measurement of the overall hemostatic response. Initial (tϭ5 minutes) blood loss was somewhat greater in TM Pro/Pro mice (Pϭ0.08), but over time (30 minutes), mutant and normal mice controlled bleeding from the wound to an identical extent.
TM Deficiency Accelerates Arterial Thrombus Growth After Acute Endothelial Injury
Platelet-rich occlusive thrombi formed in TM Pro/Pro mice after 
TM Deficiency Precipitates Stasis-Induced Thrombus Formation
The left common carotid arteries of 12 wild-type and 19 hypercoagulable TM Pro/Pro mice were permanently occluded by ligation near the carotid bifurcation. All animals recovered from the surgical intervention without complications. In all wild-type mice, thrombotic occlusion was restricted to within Ͻ1 mm from the site of ligation. In contrast, 11 TM Pro/Pro mice developed far more extensive thrombotic lesions extending over the entire length of the artery (nϭ4, Figure 1a through 1d), halfway toward the aortic arch (nϭ2), or over the distal third of the ligated vessel (nϭ5). The majority of occlusive thrombi exhibited extensive cellular organization, canalization, and/or vascular remodeling at the time of analysis (Figure 1b and 1c) . In the remaining 8 TM Pro/Pro mice, the average distance from the ligature at which the vessel was still occluded was significantly longer than that in wild-type mice. (1.81Ϯ0.5 versus 0.25Ϯ0.08 [meanϮSEM] mm, respectively; PϽ0.005). In 6 of these mice, clot remnants or a highly irregular intimal architecture suggestive of the previous presence of mural thrombi was observed (Figure 1e 
TM Deficiency Causes Increased Mortality and Altered Cytokine Production in Lipopolysaccharide-Induced Septicemia
Under ambient husbandry conditions, the TM Pro mutation was not associated with systemically increased plasma levels of IL-1␤, TNF-␣, or IL-6 (data not shown). No significant differences in steady-state mRNA levels of various mouse cytokines, endothelial cell-leukocyte adhesion molecules, or fibrinolytic regulators were detected in tissues from wild-type and mutant mice (data not shown). Intravital fluorescence microscopy was used to compare endothelial cell-leukocyte rolling interactions in mutant mice with those in control mice. The fraction of rolling leukocytes and the frequency distribution of rolling velocities in small venules of the cremaster muscle and ear skin were indistinguishable in normal and mutant mice (percent rolling cells in total leukocyte flux in ear venules, 61.2Ϯ17.1% [meanϮSD] versus 60.8Ϯ18.8% in wild-type mice; percent rolling cells in total leukocyte flux in cremaster venules, 39Ϯ16.5% versus 36Ϯ19% in wildtype mice). Antibody-mediated blocking of E-selectin led to an increase in average rolling velocities, the magnitude of which was identical in both animal groups and tissues. The fraction of rolling leukocytes was again identical in normal and mutant mice (data not shown). These data indicate that the constitutive or surgical trauma-induced expression of endothelial selectins and of their carbohydrate ligands on circulating leukocytes is not affected by the TM Pro mutation. Intraperitoneal injection of 40 mg lipopolysaccharide (LPS)/kg caused death after 72 hours in 50% of wild-type mice and was subsequently used to compare the survival of TM Pro/Pro and wild-type mice after challenge with an LD 50 of LPS. The survival of TM Pro/Pro mice was significantly impaired compared with survival of control mice (Pϭ0.012, by Mantel-Cox log-rank test): 5 of 12 wild-type mice recovered completely from LPS-induced septicemia, whereas the same dose of LPS caused earlier death in TM Pro/Pro mice, and none of the mutant mice survived beyond 5 days. Peak TNF-␣ serum levels induced by an LD 50 LPS dose were comparable in both groups of mice (Ϸ20 ng/mL). 
Weiler et al Mouse Model for Thrombomodulin Deficiency
A sublethal dose of 5 mg LPS/kg body mass caused a transient increase in IL-1␤, TNF-␣, and IL-6 levels in all experimental animals and resulted in significant genotypedependent differences in the magnitude and time course of the cytokine response (Figure 2) . TM Pro/Pro mice exhibited significantly higher serum concentrations of IL-6 and IL-1␤ and earlier maximal IL-1␤ release. The mean TNF-␣ level was Ϸ2-fold lower in TM Pro/Pro mice than in wild-type mice. In both animal groups, plasma fibrinogen concentration remained unaltered at least until 6 hours after LPS challenge but was elevated 1.7-fold after 24 hours. D-dimer levels increased in all mice as early as 2 hours after LPS administration and continued to rise until the next day. The relative increase in D-dimer levels over baseline values was similar in wild-type and mutant mice. Mean PAP levels were at all time points higher in TM Pro/Pro mice than in control mice (at 6 hours, 27.5Ϯ1.1 [meanϮSD] versus 7.9Ϯ3.5 ng/mL, respectively; PϽ0.001). Because of a relatively large (compared with baseline levels) variability, the difference in FPA levels between wild-type and mutant mice after LPS administration was not consistent. LPS caused a reduction in total tissue TM antigen to 71.5Ϯ5% and 62Ϯ9% of normal levels in the lung and brain, respectively, in both wild-type and mutant mice. In contrast, TM expression in the kidney remained unaltered. Soluble plasma TM antigen gradually increased over 6 hours after LPS administration and returned to baseline levels after 24 hours. At all time points, soluble plasma TM was substantially lower in TM Pro/Pro mice. LPS-induced fibrin deposition in the kidney, heart, spleen, and lung was more pronounced in mutant mice (Figure 3) . LPS did not elicit detectable fibrin deposition in the brain at either dose (ie, LD 50 and 5 mg/kg).
Mouse Strain-Specific Genetic Modifiers Determine the Severity of the Hypercoagulable State and Microvascular Thrombosis in TM Pro/Pro Mice
In our previous analysis of TM Pro/Pro mice with a mixed 129/C57 genetic background, the TM Pro mutation was associated with significant intravascular fibrin deposition in some, but not all, organs of mutant mice. 18 In contrast, fibrin deposition in the lung, spleen, and heart of inbred C57BL/6J TM Pro/Pro mice was not different from that observed in wild-type C57BL/6J mice ( Figure 4) . Mating of C57BL/6J TM Pro/Pro with wild-type 129SvPas mice and subsequent intercrossing of the resulting F1 hybrids yielded TM Pro/Pro mice with a mixed 129SvPas/ C57BL/6J composition identical to that present in the animal population subjected to our previous analysis. Reintroduction of the 129SvPas genetic component restored the markedly augmented fibrin deposition in the heart, lung, and spleen observed earlier (Figure 4) . ). To determine whether fibrin deposition was caused by these strain-specific differences in TM expression levels, TM antigen levels and fibrin deposition were measured in C57BL/6J TM Pro/lacZ mice possessing only 1 functional TM Pro allele. Consistent with previous findings, 18 TM 6 /L, respectively). In TM Pro/Pro mice with a mixed genetic background, red blood cell volume and hematocrit approached the values seen in wild-type 129SvPas mice (mean cell volume 48.4Ϯ1.4 fL, hematocrit 48.7Ϯ1.6%), whereas platelet counts were similar to those in wild-type C57BL/6 animals (0.6Ϯ0.1ϫ10 6 /L). Despite reduced platelet numbers in wild-type 129SvPas mice, occlusion time after FeCl 3 -induced injury was not significantly prolonged compared with C57BL/6 mice (for 129SvPas mice, 11Ϯ2.7 minutes, and for C57BL/6 mice, 9.7Ϯ2.5 minutes; Pϭ0.18). Occlusion time in mixed background TM Pro/Pro mice was comparable to that in C57BL/6 TM Pro/Pro mice (8.4Ϯ1.3 and 7.6Ϯ1.3 minutes, respectively; Pϭ0.3) and remained significantly different from that measured in C57BL/6 wild-type mice (PϽ0.05).
Discussion
We have shown previously that the introduction of a point mutation (Glu4043 Pro) in the EGF4/5-interdomain loop of the mouse TM gene disrupts the ability of TM to enhance the thrombin-mediated activation of protein C. The defect was associated with increased intravascular fibrin deposition, but mutant mice remained free from overt thrombosis and exhibited a normal life span. 18 In the present study, we chose 2 experimental models of vascular injury to determine the effects of the TM Pro mutation on the 2 major pathways leading to large-vessel thrombosis, ie, platelet-predominant thrombosis after acute endothelial injury and clot formation after stasis-induced activation of the coagulation system. Ligation of the common carotid artery reduces blood flow to a residual pulsatile mode and induces reproducible alterations of arterial wall function by a combination of neointimal hyperplasia and remodeling. 23, 28 The model is distinguished by the continued presence of a functional endothelium and is, therefore, uniquely suited to investigate the contribution of endothelial surface-associated factors to thrombosis prevention. In animals with normal coagulation systems, thrombus deposition remains localized at the site of the ligation. 23, 29 In contrast, in TM Pro/Pro mice, the model elicited extensive and persistent thrombotic occlusion with subsequent remodeling and thrombus organization. Thus, in mice, functional TM defects constitute a strong risk factor for thrombosis caused by unfettered coagulation activation under conditions of reduced blood flow. Vascular injury has been reported to cause transient TM expression by smooth muscle cells, 30, 31 which might influence vascular wall remodeling. 32, 33 Indeed, we observed induction of TM gene transcription in nonendothelial vascular wall cells in some of the ligated arteries (data not shown), and the morphometric analysis of nonoccluded vessel segments showed a tendency toward increased intimal hyperplasia in mutant mice. However, TM antigen expression in neointimal and medial smooth muscle cells was below the limit of detection with TM-specific antibodies. Therefore, the vascular pathology observed in TM Pro/Pro mice after ligationinduced stasis is likely dominated by the reduced anticoagulant capacity of the vascular endothelium. In contrast to ligation-induced injury, the topical application of a FeCl 3 -solution results in acute damage of the endothelial cell layer and formation of an occlusive platelet-rich thrombus. Reduced TM activity caused a small acceleration of plateletthrombus growth, indicating that diminished levels of soluble and/or endothelium-associated TM limit, to some extent, initial thrombus growth at sites of severe endothelial dysfunction or acute injury. Compared with the consequences of the TM Pro mutation on stasis-induced thrombosis, the effect of the mutation on platelet adhesion and/or aggregation is likely of minor importance in TM Pro/Pro mice. We have shown further that reduced TM expression/ function in mice was associated with an altered response to inflammatory challenges. Under basal conditions, there was no evidence of endothelial dysfunction or activation, because endothelial cell-leukocyte interactions were normal, as was the expression of endothelial cell-derived gene products other than TM and levels of proinflammatory cytokines. Pro/Pro mice, as judged from increased tissue fibrin deposition. The latter indicates that the procoagulant effect of reduced protein C activation is more pronounced than the potential profibrinolytic effect of reduced activation of the thrombin-activatable inhibitor of fibrinolysis under these conditions. Interestingly, the brain appeared protected from fibrin deposition even after a challenge with lethal LPS doses. This observation is congruent with our earlier findings demonstrating a remarkable resilience of the brain microvasculature toward prothrombotic challenges, which appears to be largely based on a TM-independent mechanism. Of note, endotoxin caused a similar reduction of total tissue TM antigen to 60% to 70% of baseline levels in the lung and brain of mutant and normal mice, but total tissue antigen in the kidney was unaffected, confirming earlier findings demonstrating a tissue-restricted sensitivity of TM expression to LPS. 34 The increased elaboration of IL-6 and IL-1␤ in TM Pro/Pro mice corroborates results from in vivo studies, in which infusion of soluble TM or APC into endotoxin-treated animals inhibits coagulation, prevents organ injury, and suppresses the elaboration of proinflammatory cytokines, including IL-8, IL-6, and TNF-␣. [35] [36] [37] [38] In vitro studies have shown that APC can inhibit TNF-␣ production by LPSstimulated monocytes/macrophages 35, 39 but may elicit production of IL-6 and IL-8 in endothelial cells. 40 The reduced production of TNF-␣ in TM Pro/Pro mice, which occurs concomitant with increased IL-6/IL-1␤, is difficult to reconcile with these findings. Interestingly, infusion of recombinant antithrombin III into baboons challenged with a lethal dose of Escherichia coli 41 has a similar disparate effect on the release of TNF-␣ and IL-6, augmenting the former but diminishing the latter. It warrants further experimental analysis to determine whether TM and antithrombin III modulate cytokine production through a related mechanism. 42 These observations add to a body of evidence that different anticoagulants considered for therapeutic intervention in sepsis all seem effective in dampening the coagulation reaction, yet they exert astoundingly variable effects on the production of cytokines and the regulation of fibrinolysis (see review 15 ).
Our analysis provides compelling evidence that the phenotypic penetrance of the TM Pro mutation is strongly influenced by mouse strain-specific genetic differences. In contrast to TM Pro/Pro mice with a mixed genetic background (ie, 129SvPas/C57BL/6J), inbred C57BL/6J TM Pro/Pro mice did not exhibit augmented microvascular fibrin deposition. Reintroduction of the 129SvPas genetic component reconstituted the significantly augmented fibrin deposition observed earlier. 18 The protective effect of the C57BL/6J background cannot be explained by strain-specific differences in the level of TM expression but must, therefore, depend on the presence of modifier loci of thrombosis other than TM. Despite the absence of microvascular thrombosis, C57BL/6J TM Pro/Pro mice show alterations in plasma markers of coagulation (ie, FPA and D-dimer) that indicate a hypercoagulable state with a severity similar to that reported in humans carrying the insT1689 mutation in the TM gene. 10 Reintroduction of the 129SvPas genetic component resulted in drastically increased levels of D-dimer and TAT in TM Pro/Pro mice, suggesting that augmented fibrin deposition in mixed background TM Pro/Pro mice is not caused by diminished fibrinolysis but results from augmented thrombin generation. Wild-type C57BL/6 and 129SvPas mice differ with respect to several parameters affecting hemostatic system function, most notably, platelet numbers and red blood cell volume. Although the latter might contribute to some extent to increased congestion and impediment of blood flow in the microvasculature, the mechanism underlying the mouse strain-specific differences in the phenotypic penetrance of the TM Pro mutation remains to be experimentally established. The demonstrated genetic basis of this phenomenon should allow one to pinpoint the thrombosis modifier gene loci interacting with the TM mutation and to define epigenetic variables that determine the severity of thrombosis in this animal model. Our findings validate the TM Pro/Pro mouse strain as a genetically defined animal model for the thrombophilic state secondary to reduced function of the TM-protein C pathway, which elicits a pronounced hypercoagulable state and sensitizes the animal to physiologically relevant thrombotic challenges, such as stasis, endothelial injury, and inflammation. In light of the recently demonstrated benefits of recombinant activated protein C in the treatment of acute sepsis, 43 mice carrying the TM Pro mutation could be a valuable resource for the in vivo assessment of such novel therapeutic modalities.
